

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering  
Cancer Center

[Make an Appointment](#)

[← Back](#)

[The Prasad Adusumilli Lab](#)

[Research, Diagnosis & Treatment](#)

[Refer a Patient](#)

ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Equality, diversity & inclusion](#)

[Annual report](#)

[Give to MSK](#)

New York State Empire Clinical Research Investigator Program (ECRIP)

Commission on Cancer Research Award

2011 Society of Thoracic Surgeons' "Look to the Future" Scholarship

## Current Employment

Assistant Professor of Surgery, Boston University School of Medicine, Boston, MA

## Publications

Bille A, Ahmad U, Woo KM, Suzuki K, Adusumilli PS, Huang J, Jones DR, Rizk NP. Detection of recurrence patterns after wedge resection for early stage lung cancer: rationale for radiologic follow-up. *Ann Thorac Surg*. 2016;102(4):1067-73.

Ripley RT, Suzuki K, Tan KS, Adusumilli PS, Huang J, Park BJ, Downey RJ, Rizk NP, Rusch VW, Bains M, Jones DR. Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non-small cell lung cancer. *J Thorac Cardiovasc Surg*. 2016;151(4):969-77, 79 e1-3.

Suzuki K, Park BJ, Adusumilli PS, Rizk NP, Huang J, Jones DR, Bains MS. Chest wall reconstruction using a methyl methacrylate neo-rib and mesh. *Ann Thorac Surg*. 2015;100(2):744-7.

Ahmad U, Yang H, Sima C, Buitrago DH, Ripley RT, Suzuki K, Bains MS, Rizk NP, Rusch VW, Huang J, Adusumilli PS, Rocco G, Jones DR. Resection of primary and secondary tumors of the sternum: an analysis of prognostic variables.

*Ann Thorac Surg.* 2015;100(1):215-21; discussion 21-2.

Kachala SS, Bograd AJ, Villena-Vargas J, Suzuki K, Servais EL, Kadota K, Chou J, Sima CS, Vertes E, Rusch VW, Travis WD, Sadelain M, Adusumilli PS. Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma. *Clin Cancer Res.* 2014;20(4):1020-8.

Suzuki K, Kadota K, Sima CS, Nitadori J, Rusch VW, Travis WD, Sadelain M, Adusumilli PS. Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor beta2 (IL-12Rbeta2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. *J Clin Oncol.* 2013;31(4):490-8.

Kadota K, Colovos C, Suzuki K, Rizk NP, Dunphy MP, Zabor EC, Sima CS, Yoshizawa A, Travis WD, Rusch VW, Adusumilli PS. FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma. *Ann Surg Oncol.* 2012;19(11):3598-605.

Kadota K, Suzuki K, Kachala SS, Zabor EC, Sima CS, Moreira AL, Yoshizawa A, Riely GJ, Rusch VW, Adusumilli PS, Travis WD. A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. *Mod Pathol.* 2012;25(8):1117-27.

Kadota K, Kachala SS, Nitadori J, Suzuki K, Dunphy MP, Sima CS, Travis WD, Rusch VW, Adusumilli PS. High SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: supportive evidence to reclassify pleomorphic as nonepithelioid histology. *J Thorac Oncol.* 2012;7(7):1192-7.

Kadota K, Suzuki K, Colovos C, Sima CS, Rusch VW, Travis WD, Adusumilli PS. A nuclear grading system is a strong predictor of survival in epithelioid diffuse malignant pleural mesothelioma. 2012;25(2):260-71.

Suzuki K, Kadota K, Adusumilli PS. Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients. *Cancer Immunol Immunother.* 2011;60:1721-8.

Bograd AJ, Suzuki K, Vertes E, Colovos C, Morales EA, Sadelain M, Adusumilli PS. Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma. *Cancer Immunol Immunother.* 2011;60(11):1509-27.

Suzuki K, Kachala SS, Kadota K, Shen R, Mo Q, Beer DG, Rusch VW, Travis WD, Adusumilli PS. Prognostic immune markers in non-small cell lung cancer. *Clin Cancer Res.* 2011;17(16):5247-56.

Kadota K, Suzuki K, Sima CS, Rusch VW, Adusumilli PS, Travis WD. Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma. *J Thorac Oncol.* 2011;6(5):896-904.

Suzuki K, Servais EL, Rizk NP, Solomon SB, Sima CS, Park BJ, Kachala SS, Zlobinsky M, Rusch VW, Adusumilli PS. Palliation and pleurodesis in malignant pleural effusion: the role for tunneled pleural catheters. *J Thorac Oncol.* 2011;6(4):762-7.

Servais EL, Suzuki K, Colovos C, Rodriguez L, Sima C, Fleisher M, Rusch VW, Sadelain M, Adusumilli PS. An *in vivo* platform for tumor biomarker assessment. *PLoS One.* 2011;6(10):e26722.

## Connect

[Contact us](#)

[Locations](#)

APPOINTMENTS

[800-525-2225](#)



## ▼ About MSK

[About us](#)

[Careers](#) ■

[Giving](#) ■

## ▼ Cancer Care

[Adult cancer types](#)

[Child & teen cancer types](#)

[Integrative medicine](#)

[Nutrition & cancer](#)

[Find a doctor](#)

## ▼ Research & Education

[Sloan Kettering Institute](#)

[Gerstner Sloan Kettering Graduate School](#) ■

[Graduate medical education](#)

[MSK Library](#) ■

---

[Communication preferences](#)

[Cookie preferences](#)

[Legal disclaimer](#)

[Accessibility statement](#)

[Privacy policy](#)

[Price transparency](#)

[Public notices](#)

© 2024 Memorial Sloan Kettering Cancer Center